Boehringer adds to obesity alliance with Denmark’s GubraTwo years after they started working together, Boehringer Ingelheim and Gubra have taken their obesity collaboration to a Share XBoehringer adds to obesity alliance with Denmark’s Gubrahttps://pharmaphorum.com/news/boehringer-obesity-denmarks-gubra/
Boehringer looks to enhance COPD care with new registryBoehringer Ingelheim and Optimum Patient Care are launching a new patient registry, APEX COPD (Advancing the Patient Experience Share XBoehringer looks to enhance COPD care with new registryhttps://pharmaphorum.com/news/boehringer-enhance-copd-care-new-registry/
AbbVie gets crucial US approval for psoriasis drug SkyriziWith one eye on life without its ageing $20 billion-a-year blockbuster Humira, AbbVie has got its psoriasis drug Share XAbbVie gets crucial US approval for psoriasis drug Skyrizihttps://pharmaphorum.com/news/abbvie-gets-crucial-us-approval-for-psoriasis-drug-skyrizi/
BI chief “regrets” Brexit, but continues to invest in UKThe head of Germany’s Boehringer Ingelheim has said that he “regrets” Brexit, but reassured patients in the country Share XBI chief “regrets” Brexit, but continues to invest in UKhttps://pharmaphorum.com/news/bi-chief-regrets-brexit-but-continues-to-invest-in-uk/
Boehringer’s blockbuster Spiriva under pressure, profits downBoehringer Ingelheim has announced an increase in sales for full year 2018, but a slight decline in profits, Share XBoehringer’s blockbuster Spiriva under pressure, profits downhttps://pharmaphorum.com/news/boehringer-ingelheim-2018-sales-profits/
Boehringer files for new rare disease use for nintedanib in EU, USBoehringer Ingelheim has filed for a new use for its lung drug nintedanib in the US and Europe, Share XBoehringer files for new rare disease use for nintedanib in EU, UShttps://pharmaphorum.com/news/boehringer-files-for-new-rare-disease-use-for-nintedanib-in-eu-us/
AZ backs diabetes drug Farxiga with new cardio analysisAstraZeneca continues to make the case for its Farxiga diabetes drug, highlighting a cardiology analysis that it hopes Share XAZ backs diabetes drug Farxiga with new cardio analysishttps://pharmaphorum.com/news/az-backs-diabetes-drug-farxiga-with-new-cardio-analysis/
Boehringer follows Sanofi with job cuts in FranceBoehringer Ingelheim has confirmed it plans to axe more than 10% of its workforce in France, or more Share XBoehringer follows Sanofi with job cuts in Francehttps://pharmaphorum.com/news/boehringer-follows-sanofi-with-job-cuts-in-france/
Boehringer Ingelheim axes biosimilars development outside USBoehringer Ingelheim has said it has axed ex-US development of its biosimilars, focusing instead on getting its Humira Share XBoehringer Ingelheim axes biosimilars development outside UShttps://pharmaphorum.com/news/boehringer-ingelheim-axes-biosimilars-development-outside-us/
